Drug Designing: Open Access
Open Access

Amplifying the role of collaboration globally for neglected and commercial disease drug discovery

International Conference and Expo on Drug Discovery & Designing

August 11-13, 2015 Frankfurt, Germany

Barbara Holtz, Charlie Weatherall and Barry Bunin

Posters-Accepted Abstracts: Drug Des

Abstract :

Collaborative innovation is uniquely able to realize the economics of well-integrated specialization required for drug discovery.
Particularly in the neglected infectious disease areas lacking a profit motive, better collaborative tools are fundamentally
important to catalyze faster progress. Layering unique collaborative capabilities upon requisite drug discovery database functionality
unlocks and amplifies synergy between biologists and chemists. Researchers need to have tools that balance individual needs for
robust, intuitive registration and bioactivity analyses while at the same time facilitating collaborations with secure data partitioning,
communication, and group engagement. Since collaborative technology is “therapeutic area agnostic”, it has generally been proven
equally applicable for commercial applications. Representative commercial case studies include broad consortia such as the NIH
Neuroscience Blueprint collaboration between drug discovery companies, CROs, together with seven leading academic biology
laboratories as part of a 5-year government contract to advance new CNS drugs into the clinic. As well as more focused examples
following the lean venture funded model such as the collaboration between Acetyton Pharmaceuticals with Harvard and a Chinese
CRO to bring a selective HDAC inhibitor into the clinic. Finally, by spanning the continuum of private, collaborative and public
modes, researchers globally can now seamlessly collaborate across the pre-competitive and competitive landscape.